Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Hemophilia A is an X-linked bleeding disorder caused by mutations in the factor VIII (FVIII) gene (F8). Treatment with recombinant or plasma-derived FVIII replacement therapy is standard therapy. A major problem in treating hemophilia A patients with therapeutic FVIII is that 20% to 30% of these patients produce neutralizing anti-FVIII antibodies (inhibitors) because they are not immunologically tolerant to this human protein. Hence, there is a need to establish tolerogenic protocols to FVIII epitopes. To specifically target FVIII-specific B cells, we engineered immunodominant FVIII domains (A2 and C2) as a chimeric antigen receptor expressed by both human and murine cytotoxic T cells. This FVIII domain engineered B-cell antibody receptor (BAR) that expresses T cells was capable of killing FVIII-reactive B-cell hybridomas in vitro and in vivo. Moreover, FVIII BAR CD8 T cells blocked the development of specific antibody from unimmunized spleen cells stimulated polyclonally with lipopolysaccharide in vitro. In addition, adoptive transfer of FVIII A2- and C2-BAR CD8 T cells significantly reduced the anti-FVIII antibody formation in hemophilic mice. These data suggest that BAR-engineered T cells are a promising approach for future prophylactic treatment for patients with severe hemophilia A who are at high risk of developing inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BAR T cells successfully eliminated FVIII reactive B cells in vitro and in vivo [238].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [238]
Citations
Cites
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Ellebrecht, C. T., Bhoj, V. G., Nace, A., Choi, E. J., Mao, X., Cho, M. J., Di Zenzo, G., Lanzavecchia, A., Seykora, J. T., Cotsarelis, G., et al. (2016) · Science · doi:10.1126/science.aaf6756 · Cited by 738
Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00005 · Cited by 701 · cited 2×
“Sorted human T cells were expanded with antiCD3 (Clone OKT3; 0.5 mg/mL) in the presence of 60 Gy–irradiated PBMCs and IL-2.”
MethodInfluentialRemote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
The JAM test A simple assay for DNA fragmentation and cell death
Matzinger, P. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90325-a · Cited by 599 · cited 1×
“Percent-specific lysis was calculated as described previously.(13) In vivo B-cell hybridoma killing in NSG mice Male NSG mice were injected IV with 2 3 10(6) BO2C11 B-cell hybridoma cells on day 1.”
MethodTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 2×
“Materials and methods Mice FVIII exon 16 knockout mice (E16) on a C57BL/6 background were used as the model for HA; these were derived from a colony belonging to Leon Hoyer, MD, at the American Red Cross.(10,11) NSG (NOD.”
MethodInduction of immunoglobulin and antibody synthesis in vitro by lipopolysaccharides
Anderson, J., Sjöberg, O., & Moller, G. (1972) · European Journal of Immunology · doi:10.1002/eji.1830020410 · Cited by 427 · cited 1×
“Naı̈ve B cells were cultured with or without lipopolysaccharide (LPS; 1 mg/mL) for 48 hours for polyclonal activation.(15,16) For BAR-mediated FVIII-specific naı̈ve B-cell killing experiments, A2/C2-BAR or OVA-BAR CD8 T cells were mixed at a 5:1 ratio with isolated B cells, cultured in the presence of LPS for 48 hours…”
MethodGouw, S. C., van den Berg, H. M., Oldenburg, J., Astermark, J., de Groot, P. G., Margaglione, M., Thompson, A. R., van Heerde, W., Boekhorst, J., Miller, C. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-379453 · Cited by 358 · cited 1×
“However, because patients are not immunologically tolerant to FVIII, an anti-drug antibody response can occur in up to 30% of the patients receiving replacement FVIII treatment.(2,3) These immunoglobulin G (IgG) antibodies (called inhibitors) neutralize the function of therapeutic FVIII drugs.”
BackgroundAn oxygen sensitive self-decision making engineered CAR T-cell
Juillerat, A., Marechal, A., Filhol, J. M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., & Poirot, L. (2017) · Scientific Reports · doi:10.1038/srep39833 · Cited by 225
Prevention and treatment of factor VIII inhibitors in murine hemophilia A
Qian, J., Collins, M., Sharpe, A. H., & Hoyer, L. W. (2000) · Blood · doi:10.1182/blood.v95.4.1324.004k25_1324_1329 · Cited by 168
Sakemura, R., Terakura, S., Watanabe, K., Julamanee, J., Takagi, E., Miyao, K., Koyama, D., Goto, T., Hanajiri, R., Nishida, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0043 · Cited by 161
Cited by
CAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 504
“A similar approach specifically targeted dysfunctional B cells in a mouse model of haemophilia 41 .”
Autoantibodies in neurological disease
Prüss, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00543-w · Cited by 319
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“BAR T cells successfully eliminated FVIII reactive B cells in vitro and in vivo [238].”
BackgroundImmunogenicity of Protein Pharmaceuticals
Dingman, R. K., & Balu‐Iyer, S. V. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.014 · Cited by 182
CAR-based therapies: opportunities for immuno-medicine beyond cancer
Aghajanian, H. K., Rurik, J. G., & Epstein, J. A. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00537-5 · Cited by 135
Metadata
- Authors
- Parvathaneni, K., & Scott, D. W.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2018-09-19
- Volume
- 2
- Issue
- 18
- Pages
- 2332-2340
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC6156881
- OpenAlex
- W2891600806
- Cited by
- 56
- References
- 25
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 7 · 2020: 10 · 2019: 6 · 2018: 1
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R21HL127495, R01HL061883)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- hemophilia A, factor VIII, chimeric antigen receptor, cytotoxic T lymphocytes, immune tolerance, adoptive T cell therapy, neutralizing antibodies, prophylaxis
- MeSH terms
- Animals, B-Lymphocytes, Cytotoxicity, Immunologic, Factor VIII, Hemophilia A, Humans, Lymphocyte Activation, T-Lymphocytes, Cytotoxic, Gene Expression, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo. https://app.cochat.ai/papers/10.1182/bloodadvances.2018018556
- The paper
- Parvathaneni, K., & Scott, D. W. (2018). Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo. Blood Advances. https://doi.org/10.1182/bloodadvances.2018018556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.